Moderna to file for EU approval of mRNA-1273 vaccine
COVID-19 mRNA vaccine developer Moderna Inc reported it will file for FDA and EMA authorisation of mRNA-1273 based on Phase III results.
Drug set to rescue COVID-19 patients at ICUs
Aviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients.
Polyphor AG bags funding for murepavadin
Polyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.
EU COVID-19 antibody ready for clinical trials
As investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics candidate COR101 is set to enter clinical testing.
COVID-19: Moderna reports promising interim results
After BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%.
BioNTech reports high efficacy of COVID-19 vaccine
Interim data on BioNtechs/Pfizers COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA.
Vifor Pharma inks $340m deal with Angion Biomedica Inc.
Swiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedicas experimental kidney drug ANG-3777.
Cell and gene therapy specialist Minaris expanding
Japanese CDMO Minaris Regenerative Medicine Co. Ltd will invest US$64.5m to expand its facilities in Europe and Asia.
Protein Brewery raise 22m in Series A
Lead investor Novo Growth has led a 22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.
Galecto raise US$85m in Nasdaq IPO
HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.